Proteomics of pancreatic cancer

Pancreas

Volumn 36, Issue 4, 2008, Pages 329-336

  Gräntzdörffer, Ilona ^a   Carl McGrath, Stacy ^a   Ebert, Matthias P ^b   Röcken, Christoph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Pancreatic cancer; Proteome; Proteomics; Review

Indexed keywords

ALPHA 2 MACROGLOBULIN; ALPHA ENOLASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; BETA 2 MICROGLOBULIN; BETA1 INTEGRIN; CA 19-9 ANTIGEN; CALCYCLIN; CALRETICULIN; CATHEPSIN D; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; COMPLEMENT FACTOR H; COPPER ZINC SUPEROXIDE DISMUTASE; FASCIN; FIBRINOGEN; GALECTIN 1; HAPTOGLOBIN ALPHA; HAPTOGLOBIN ALPHA1; HAPTOGLOBIN ALPHA2; HEMOPEXIN; LIPOCORTIN 2; MANGANESE SUPEROXIDE DISMUTASE; PIGMENT EPITHELIAL DIFFERENTIATING FACTOR; PREALBUMIN; PROTEIN; PROTEOME; VITAMIN D BINDING PROTEIN;

ANALYTIC METHOD; ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DISEASE COURSE; ELECTROSPRAY MASS SPECTROMETRY; GEL ELECTROPHORESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LASER CAPTURE MICRODISSECTION; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SMOKING; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TWO DIMENSIONAL ELECTROPHORESIS; WESTERN BLOTTING;

HUMANS; NEOPLASM PROTEINS; PANCREATIC JUICE; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 42549101681     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815cc452     Document Type: Review

References (40)

1. Hamilton SR, Aalton LA. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press; 2000.
2. Hezel AF, Kimmelman AC, Stanger BZ, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2006;20:1218-1249.
3. Karhu R, Mahlamaki E, Kallioniemi A. Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosomes Cancer. 2006;45:721-730.
4. Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol. 2006;20:211-226.
5. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006;13:286-295.
6. Benassai G, Mastrorilli M, Quarto G, et al. Factors influencing survival after resection for ductal adenocarcinoma of the head of the pancreas. J Surg Oncol. 2000;73:212-218.
7. Brennan MF, Kattan MW, Klimstra D, et al. Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg. 2004;240:293-298.
8. Gebhardt C, Meyer W, Reichel M, et al. Prognostic factors in the operative treatment of ductal pancreatic carcinoma. Langenbecks Arch Surg. 2000;385:14-20.
9. Kuhlmann KF, de Castro SM, Wesseling JG, et al. Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer. 2004;40:549-558.
10. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
11. Luttges J, Schemm S, Vogel I, et al. The grade of pancreatic ductal carcinoma is an independent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol. 2000;191:154-161.
12. Millikan KW, Deziel DJ, Silverstein JC, et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 1999;65:618-623.
13. Moon HJ, An JY, Heo JS, et al. Predicting survival after surgical resection for pancreatic ductal adenocarcinoma. Pancreas. 2006;32:37-43.
14. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
15. Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243-249.
16. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935-949.
17. Wenger FA, Peter F, Zieren J, et al. Prognosis factors in carcinoma of the head of the pancreas. Dig Surg. 2000;17:29-35.
18. Ridwelski K, Meyer F, Fahlke J, et al. Value of cytokeratin and Ca 19-9 antigen in immunohistological detection of disseminated tumor cells in lymph nodes in pancreas carcinoma. Chirurg. 2001;72:920-926.
19. Niedergethmann M, Rexin M, Hildenbrand R, et al. Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol. 2002;26:1578-1587.
20. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313-5327.
21. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267-275.
22. Röcken C, Ebert MP, Roessner A. Proteomics in pathology, research and practice. Pathol Res Pract. 2004;200:69-82.
23. Fels LM, Buschmann T, Meuer J, et al. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer. Dig Dis. 2003;21:292-298.
24. Hu L, Evers S, Lu ZH, et al. Two-dimensional protein database of human pancreas. Electrophoresis. 2004;25:512-518.
25. Gronborg M, Bunkenborg J, Kristiansen TZ, et al. Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res. 2004;3:1042-1055.
26. Shekouh AR, Thompson CC, Prime W, et al. Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics. 2003;3:1988-2001.
27. Lu Z, Hu L, Evers S, et al. Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics. 2004;4:3975-3988.
28. Shen J, Person MD, Zhu J, et al. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004;64:9018-9026.
29. Chen R, Yi EC, Donohoe S, et al. Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology. 2005;129:1187-1197.
30. Lin Y, Goedegebuure PS, Tan MC, et al. Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res. 2006;5:2169-2176.
31. Deng R, Lu Z, Chen Y, et al. Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas. 2007;34:310-317.
32. Bloomston M, Zhou JX, Rosemurgy AS, et al. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006;66:2592-2599.
33. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004;10:860-868.
34. Bhattacharyya S, Siegel ER, Petersen GM, et al. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia. 2004;6:674-686.
35. Scarlett CJ, Smith RC, Saxby A, et al. Proteomic classification of pancreatic adenocarcinoma tissue using protein chip technology. Gastroenterology. 2006;130:1670-1678.
36. Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005;65:10613-10622.
37. Rosty C, Christa L, Kuzdzal S, et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis- associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002;62:1868-1875.
38. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205-214.
39. Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005;41:2213-2236.
40. Ro ̈cken C, Ebert MP. Pancreatic cancer proteome. Gastroenterology.1 2006;130:1017-1018.